# Amgen Type: Company Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/amgen Canonical HTML page: https://gethealthbrief.com/entity/amgen ## Timeline - **2026-07-16**: FDA approves Merck's Lipfendra — The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients. - **2026-05**: Marty Makary resigns as FDA Commissioner — Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure. - **2026-03-08**: Q4 2025 Preview — Analysts set expectations for oncology-driven revenue growth. - **2025-01-01**: Loqtorzi Launch — Full commercial ramp-up of the first-in-class PD-1 for NPC. - **2024-06-01**: Yusimry Divestiture — Sale of adalimumab biosimilar to HK King-Friend for $40M. - **2024-01-01**: Cimerli Divestiture — Coherus sells its ranibizumab biosimilar to Sandoz for $170M. ## Recent coverage (7 stories) ### Insurer Pocketed $7,700/Month Drug Coupon, Forcing Patient to Pay $10,600 2026-07-27 11:00:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care. Full story: https://gethealthbrief.com/story/copay-accumulator-patient-impact ### Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved 2026-07-16 23:20:10 · Sentiment: Bullish · Impact: 8/10 · Sources: 7 The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol. Full story: https://gethealthbrief.com/story/merck-lipfendra-oral-pcsk9-pill-59-percent-ldl-cut-health-systems ### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions 2026-07-16 22:00:46 · Sentiment: Very Bullish · Impact: 9/10 · Sources: 132 The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol. Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access ### NovoCure’s $655M Revenue Signals a Shift in Direct-to-Patient Cancer Care 2026-06-28 04:07:26 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics. Full story: https://gethealthbrief.com/story/novocure-direct-patient-model-healthcare-2026 ### Hong Kong Attracts $191.5B Amgen for Health Tech Boost 2026-04-21 02:09:05 · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition. Full story: https://gethealthbrief.com/story/hong-kong-health-scheme-impact ### Coherus BioSciences Q4 Preview: Oncology Pivot and Udenyca Growth in Focus 2026-03-08 22:51:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures. Full story: https://gethealthbrief.com/story/coherus-biosciences-q4-2025-earnings-preview-oncology-pivot ### Breaking the Silence: The Shift Toward Shared Decision-Making in Statin Therapy 2026-02-22 10:28:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 3 A growing movement in cardiovascular care is challenging the 'prescribe-first' mentality of statin therapy, emphasizing patient autonomy and shared decision-making. As clinical guidelines evolve, the healthcare industry is grappling with how to balance standardized protocols with individualized patient preferences and risk profiles. Full story: https://gethealthbrief.com/story/statin-therapy-shared-decision-making-trends --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.